Why TearLab Corp. Shares Dipped

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of TearLab (NASDAQ: TEAR  ) , an ophthalmic (i.e., eye-related) medical device company focused on helping diagnose dry eye disease, dipped as much as 11% after the company reported its third-quarter earnings results.

So what: For the quarter, TearLab reported a whopping 247% increase in revenue to $4.2 million as it received a total of 467 orders for its proprietary TearLab Osmolarity systems for diagnosing dry eye disease. Net loss also shrank modestly to just $4.2 million, or $0.13 per share, from $4.6 million, or $0.17 per share a year ago. Both results were right in line with Wall Street's expectations.

Now what: You might be wondering, "If TearLab's results met expectations, why is it getting pounded today?" I believe the answer lies in witnessing the incredible growth of ophthalmic therapies like Regeneron Pharmaceuticals' Eylea. Investors have observed this and a number of smaller drugs to treat eye diseases prosper over the past year and have been expecting an almost unrealistic ramp-up out of TearLab. Admittedly, I would much rather wait for TearLab to get closer to profitability before even considering jumping on board, but today's move lower appears to be more a fault of investors' frothy hopes and emotions than anything TearLab had to report.

Another revolutionary growth stock you should be watching
TearLab's 247% revenue growth is certainly nothing for investors to gloss over -- but neither is this incredible tech stock, which is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 20, 2014, at 5:14 PM, ophthoinCali wrote:

    This product is not cost effective, I have paid $8000 for this lab in California, but only gotten reimbursed $2000. The insurance companies have denied claims. Do not get Tearlab yet until this is resolved.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2725108, ~/Articles/ArticleHandler.aspx, 9/26/2016 8:24:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
TEAR $0.66 Down -0.05 -7.13%
TearLab CAPS Rating: *